## RARE: Ultragenyx Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 8.7% in mid entry zone (4.0-10.0%), top 6% cross-sectional ranking. Short-term MRS_5 (5.6%) confirms momentum alignment. Strong momentum (+6.4% 5-day acceleration). Outperforming sector by 8.9%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($33.25)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Skandinaviska Enskilda Banken AB publ Has $2.46 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE**
- Source: MarketBeat | 20251203T130921 | Somewhat-Bearish | Relevance: 100%
- Skandinaviska Enskilda Banken AB publ significantly increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 108.1% in the second quarter, now owning 67,720 shares valued at approximately $2.46 million. Other institutional investors also boosted their holdings, with institutional ownership of Ultragenyx now standing at about 97.67%. Despite a "Moderate Buy" consensus rating and an average price target of $80.23, Ultragenyx recently missed Q3 earnings and revenue estimates, and its stock trades well below the target at around $33.37.

**2. Ultragenyx Pharmaceutical (RARE): Evaluating Valuation After Analyst Commentary on Setrusumab Progress and Growth Outlook**
- Source: Sahm | 20251201T042432 | Somewhat-Bullish | Relevance: 100%
- Ultragenyx Pharmaceutical (RARE) has seen renewed investor optimism and a 16% 90-day share price return due to analyst commentary on its setrusumab program, strong revenue growth, and advancing late-stage drug candidates. Despite a 12-month total shareholder return of -27%, analysts widely consider the stock undervalued, with a fair value of $83.40 compared to its current price of $34.75. The company's robust clinical pipeline, including five Phase III programs and upcoming BLA submissions and data readouts, is expected to significantly accelerate revenue growth.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.36M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-0.8%)
- JPMORGAN CHASE & CO: 8.3% (+146.0%)
- FMR, LLC: 7.6% (+179.6%)
- Blackrock Inc.: 6.7% (+2.7%)
- Sands Capital Manage: 3.9% (-4.4%)

### Key Risks

1. Elevated short interest (9.2%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +6.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Revenue growth strong at 21% YoY. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.3B |
| Beta | 0.16 |
| 52W Range | $25.81 - $46.50 |
| Short Interest | 9.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.24 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from 2.3% to 8.7% (+6.4% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 94th percentile. MRS_5 at 5.6% confirms short-term momentum alignment. AM_20 at 10.8% shows strong absolute momentum above own 20MA. Outperforming sector by 8.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +F0N (Breakout).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 8.69% (CS: 94) | Strong |
| RSI_14 | 63.4 | Neutral |
| MACD Histogram | 0.25 | Bullish |
| vs SMA20 | 1.107x | Above |
| vs SMA50 | 1.123x | Above |
| vs SMA200 | 1.073x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $36.45
- **Stop Loss:** $33.25 (8.8% risk)
- **Target:** $41.25 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 296
- **Position Value:** $10,789.20
- **Portfolio %:** 10.79%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-12 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.21 | $-1.81 | -49.7% |
| 2025Q2 | $-1.32 | $-1.17 | +11.4% |
| 2025Q1 | $-1.64 | $-1.57 | +4.4% |
| 2024Q4 | $-1.27 | $-1.39 | -9.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*